Retrospective Study on Complications and Adverse Effects of Treatment with Thrombin-Like Enzymes - A Multicentre Trial

Z S Latallo; Participants of the trial: S. Balkuv-Ulutin, Istanbul, Turkey; J. F. Donahoe, North Chicago, USA; K. Fukutake, Tokyo, Japan; P. Griguerand M. Brochier, Tours, France; H. C. Kwaan, Chicago, U.S.A.; S. Lopaciukand J. A. Meissner, Warsaw, Poland; M. Martin, Engelskirchen, FRG; C. R. M. Prentice, G. D. 0. Lowe and C. D. Forbes, Glasgow, UK; A. A. Sharp, Oxford, UK; H. Vi nazzer, Linz, Austria; H. Wegner, Leipzig, GDR; E. Wenzel, Homburg/Saar, FRG; Data Processing and Computer Analysis: W. Borkowski, B. Swiatczak-Szenk, J. Kukowska and J. Labanowski

doi:10.1055/s-0038-1665266

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1983; 50(02): 604-609
DOI: 10.1055/s-0038-1665266

International Committee Communications

Schattauer GmbH Stuttgart

Retrospective Study on Complications and Adverse Effects of Treatment with Thrombin-Like Enzymes - A Multicentre Trial

Z S Latallo

The Department of Radiobiology, Institute of Nuclear Research, Warsaw, Poland

,

Participants of the trial: S. Balkuv-Ulutin, Istanbul, Turkey; J. F. Donahoe, North Chicago, USA; K. Fukutake, Tokyo, Japan; P. Griguerand M. Brochier, Tours, France; H. C. Kwaan, Chicago, U.S.A.; S. Lopaciukand J. A. Meissner, Warsaw, Poland; M. Martin, Engelskirchen, FRG; C. R. M. Prentice, G. D. 0. Lowe and C. D. Forbes, Glasgow, UK; A. A. Sharp, Oxford, UK; H. Vi nazzer, Linz, Austria; H. Wegner, Leipzig, GDR; E. Wenzel, Homburg/Saar, FRG, Data Processing and Computer Analysis: W. Borkowski, B. Swiatczak-Szenk, J. Kukowska and J. Labanowski › Author Affiliations

Abstract

PDF Download

Keywords

Treatment - Complications - Retrospective study

PDF (423 kb)

References

References
1 Stocker K. Characterization of ancrod and batroxobin. In: Fibrinolytics and antifibrinolytics Markwardt F. (ed) Handbuch d. Experimentellen Pharmacologie 1978; 46: 454-484
2 Kakkar VV, Flanc C, Howe CT, O’Shea M, Flute PT. Treatment of deep vein thrombosis. A trial of heparin, streptokinase and arvin Br Med J 1969; 1: 806-810
3 Davies JA, Merrick MV, Sharp AA, Holt JM. Controlled trial of ancrod and heparin in treatment of deep-vein thrombosis of lower limb. Lancet 1972; 1: 113-115
4 Tibbutt DA, Williams EW, Walker MW, Chesterman CN, Holt JM, Sharp AA. Controlled trial of ancrod and streptokinase in the treatment of deep vein thrombosis of lower limb. Br J Haematol 1974; 27: 407-414
5 Leube G, Sondem W. Folia Angiologica 1975; 23: 411 op cit. In Prentice CR M, Lowe GD O, Belch JJ F, Forbes CD. The role of defibrinating agents in the treatment of vascular disorders. In: Vascular occlusion: Epidemiological, pathophysiological and therapeutics aspects Tesi M, Dormandy J. (eds) Serono Symposium 1981; 37: 399-404
6 Martin M, Hirdes E, Auel H. Defibrinogenation treatment in patients suffering from severe intermittent claudication - a controlled study. Thromb Res 1976; 9: 47-57
7 Tonnesen KH, Sager PH, Gormsen J. Treatment of severe foot ischaemia by defibrination with ancrod: a randomized blind study. Scand J Clin Lab Invest 1978; 38: 431-435
8 Lowe GD O, Dunlop DJ, Lawson DH, Pollock JG, Watt JK, Forbes CD, Prentice CR M, Drummond MM. Double-blind controlled clinical trial of ancrod for ischemic rest pain of the leg. Angiology 1982; 33: 46-50
9 Wolf GK. Arvin in peripheral arterial circulatory disorders: controlled multicentre trials. Eur J Clin Pharmacol 1976; 9: 387-392
10 Lowe GD O, Morrice JJ, Fulton A, Forbes CD, Prentice CR M, Barbenel JC. Subcutaneous ancrod after operation for fractured hip - a dose-ranging and feasibility study. Thromb Haemostas 1978; 40: 134-143
11 Belch JJ F, Meek DR, Lowe GD O, Campbell AF, Young AB, Forbes CD, Prentice CR M. Subcutaneous ancrod in prevention of deep vein thrombosis after hip replacement surgery. Thromb Res 1982; 25: 23-31
12 Latallo ZS. Report of the task force on clinical use of snake venom enzymes. Thromb Haemostas 1978; 39: 768-774
13 Kakkar VV, Howe CT, Flanc C, Clarke MB. Natural history of postoperative deep-vein thrombosis. Lancet 1969; 2: 230-232
14 Thomas DP. Heparin in the prophylaxis and treatment of venous thromboembolism. Semin Hematol 1978; 15: 1-17
15 Urokinase Pulmonary Embolism Trial Study Group. Urokinase pulmonary embolism trial. Phase 1 results. A cooperative study. JAMA. 1970 214. 2163-2172
16 Salzman EW, Deykin D, Shapiro RM, Rosenberg R. Management of heparin therapy - controlled prospective trial. N Engl J Med 1975; 292: 1046-1051
17 Latallo ZS, Lopaciuk S. New approach to thrombolytic therapy. The use of defibrase in connection with streptokinase Thrombos Diathes Haemorrh 1973; Suppl 56: 253-255
18 Carreras LO. Thrombosis and thrombocytopenia induced by heparin. In Clinical usage of heparin. Present and future trends Verstraete M, Machin SJ. (eds) 1980; pp 64-80
19 Bell WR, Tomasulo PA, Alving BM, Duffy TP. Thrombocytopenia occurring during the administration of heparin. A prospective study in 52 patients Ann Intern Med 1976; 85: 155-160
20 Nelson JC, Lemer RG, Goldstein R, Cagin NA. Heparin-induced thrombocytopenia. Arch Intern Med 1978; 138: 548-552
21 Barlow GH, Lewis LJ, Finley R, Martin D, Stocker K. Immunochemical identification of ancrod (A38414) and reptilase (defibrase). Thromb Res 1973; 2: 17-22